11 / 11
Page 39
Volume 2
DEMENTIA AND DEMENTIA CARE
ADVANCES IN ADDICTION SCIENCE AND MEDICINE
July 24-25, 2019 | Rome, Italy
10
th
International Conference on
2
nd
World Congress on
&
Addiction Science 2019 & Dementia Care 2019
July 24-25, 2019
Journal of Clinical Psychiatry and Neuroscience
J Clin Psychiatr Neurosci, Volume 2
Introducing “Precision Addiction Management (PAM®)” utilizing polymorphic
matched alogarithms and Pro-Dopamine regulation to combat Reward Deficiency
Behaviors (RDS) including Substance Use Disorder (SUD) globally
Kenneth Blum*
1, 2
, Marjorie C Gondré-Lewis
2,3,4
, David Baron
1,2
, DO Lisa Lott
2
, Jessica Ponce-Rodriquez
2
, Mark Moran
2
,
Lyle Fried
5
, Mauro Ceccanti
2,6
, Raju Hajela
7
, Rajendra D Badgaiyan,
2,8
1
Western University Health Sciences Graduate School of Biomedical Sciences, USA
2
Geneus Health, USA
3
Howard University, USA
4
Howard University College of Medicine, USA
5
Transformational Treatment Center, USA
6
University of Rome, Italy
7
University of Calgary, USA
8
Ichan School of Medicine at Mount Sinai, USA
R
esearch into the neurogenetic basis of addiction identified and characterized by Reward Deficiency Syndrome (RDS) includes
all drug and non-drug addictive, obsessive and compulsive behaviors. This keynote presents a new model for the prevention
and treatment of RDS behaviors based on objective biologic evidence. Currently, research directed toward improving treatment
for highly drug-dependent patients in underserved populations is the basis of an NIH grant awarded to Drs. Kenneth Blum and
Marjorie Gondré-Lewis. The grant explores utilization of the Genetic Addiction Risk Score (GARS®) and the neuronutrient pro-
dopamine regulator KB220. The development of GARS followed seminal research in 1990, whereby, Blum’s group identified
the first genetic association with severe alcoholism. The non-invasive GARS test identifies and measures the total number of
risk alleles of genes and catabolic enzymes affecting an individual's neurochemical hypodopaminergic function and has been
associated in hundreds of studies with RDS behaviors. In an unpublished study, the GARS predicted drug and alcohol severity
predisposition as measured by the Addiction Severity Index (ASI) [≤ 4 alleles for Drug & ≤ 7 alleles for Alcohol]. Genotyping
data on approximately 1000 subjects [addicted, chronic pain, opioid maintained and non-addicted] will be presented including
Italian subjects. “Precision Addiction Management” (PBM®) uses the GARS to customize KB220PAM formulations to deliver
putative dopamine homeostasis based on developed algorithms matched to polymorphic results. Presented evidence derived from
animal and human studies using BOLD neuroimaging and behavioral methodologies, support homeostatic activation of brain
dopamine in the reward circuitry by KB220PAM, as well as anti-substance seeking and modification of RDS behaviors. RDS
encompasses behaviors like PTSD, ADHD, over-eating, shopping, hoarding and related RDS cognitive insults. Combating the
drug crisis requires PBM across ethnic groups, to bring dopamine homeostasis to those born with RDS predisposition. It is the
goal through this novel model that by using PBM the addiction field will have a synergistic tool along with MAT or even alone,
to overcome dopamine dysregulation either surfeit (adolescents) or deficit (adults) by the induction of “dopamine homeostasis.